2019年10月30日星期三

Abbkine P53 antibody helps basic cancer research!

P53 gene, human tumor suppressor gene. The gene encodes a protein with a molecular weight of 43.7KDa, but is named P53 because the protein band appears at 53KDa shown by Marker. Wild-type p53 causes cancer cells to apoptosis, thus preventing canceration; But also has the function of helping cell genes repair defects; Studies have found that mutant p53 can enhance canceration. 50% of human tumors are related to P53 gene. Currently, there are liver cancer, breast cancer, bladder cancer, gastric cancer, colon cancer, prostate cancer, soft tissue sarcoma, ovarian cancer, brain tumor, lymphocyte tumor, esophageal cancer, lung cancer, osteosarcoma, etc. P53 mutation in human tumors is mainly in highly conserved regions, with the highest mutation at 175, 248, 249, 273, 282 sites, and different types of tumors.  





P53 has a very short half-life, so it is almost undetectable in unstressed cells. This is mainly realized by the continuous ubiquitination of p53 and the degradation of 26S proteasome in the later stage under the action of its inhibitor MDM2. Cell stress signals such as DNA damage can inhibit ubiquitination of p53 and lead to its stabilization and activation. Once p53 is activated, it will bind to its downstream target regulatory elements and regulate its transcription. Therefore, various cell therapy schemes based on different tumor inhibition functions of p53 can be started. Just because past studies have shown that p53 gene mutations exist in about half of cancers, scientists regard them as important targets for developing new cancer therapies.





Mutant p53 promotes adaptive responses to cancer-related stress conditions to support tumor progression.

Abbkine P53 Antibody Helps Basic Cancer
Research! Basic information about the product:





Product name
#CAT
Reactivity Applications
Dilution ratio
p53 Polyclonal Antibody ABP0110   Human, Monkey, Mouse, Rat
WB/IF/IHC-P/ELISA

WB (1:500-1:2000)
IF (1:200-1:1000)
IHC-P (1:100-1:300)
ELISA  (1:10000).

Abbkine P53 Antibody verification results:





Western Blot analysis of various cells using p53 Polyclonal Antibody diluted at 1:1000.
Immunofluorescence analysis of human liver tissue. 1, p53 Polyclonal Antibody (red) was diluted at 1:200 (4°C, overnight). 2, Cy3 Labeled secondary antibody was diluted at 1:300 (room temperature, 50min). 3, Picture B: DAPI (blue) 10min. Picture A: Target. Picture B: DAPI. Picture C: merge of A+B.
Immunohistochemical analysis of paraffin-embedded mouse testis tissue. 1, p53 Polyclonal Antibody was diluted at 1:200 (4°C, overnight). 2, Sodium citrate pH 6.0 was used for antibody retrieval (>98°C, 20min). 3, secondary antibody was diluted at 1:200 (room temperature, 30min). Negative control was used by secondary antibody only.

2019年10月15日星期二

IL-6: Target Molecule for Cytokine Storms

Interleukin-6 (IL-6) is a multi-effect cytokine
that plays an important role in host defense by regulating immune and
inflammatory reactions. IL-6 is mainly produced by macrophages, T lymphocytes
and B lymphocytes. When the body has inflammatory reaction or infection,
various cytokines such as virus, endotoxin and tumor necrosis factor can induce
the body to produce IL-6. The biological effects of IL-6 are mainly reflected
in inducing B cell differentiation to produce immunoglobulin, promoting T cell
proliferation and growth, enhancing blood cell differentiation and its
anti-tumor effect, promoting bone marrow hematopoietic stem cell proliferation,
etc.





IL-6 is an important member of cytokine network and plays a central role in acute inflammatory reaction. The production of IL-6 induces the production of C-reactive protein (CRP) and procalcitonin (PCT), which are directly related to inflammatory diseases and infection degree. IL-6 can diagnose early inflammation and warn the occurrence of sepsis faster. In addition, the half-life of IL-6 is shorter than CRP and PCT, which can reflect the effect of antibiotic treatment faster and better reflect the prognosis of patients. At the same time, IL-6 can be used as a biomarker of disease severity and prognosis indicators in cytokine storms, and its expression is superior to TNF-α and IL-1. A large number of research results show that IL-6 is a suitable target molecule for cytokine storms.





If you are studying IL-6 or are about to study IL-6, the recommended IL-6 cytokines are as follows:






Product
name


#cat

Sequence

Purity

Expressed
Host


Endotoxin

Formulation

Human
IL-6 protein

PRP100120

Human IL6
(NP_000591.1) (Val 30-Met 212)

>
95%

E.
coli

<1EU/μg

lyophilized
powder

Mouse IL-6 protein

PRP100371

Mouse
IL6 (P08505) (Phe25-Thr211)

>
95%

E.
coli

<1EU/μg

lyophilized
powder

SDS-PAGE analysis:





Human IL-6 protein




Mouse IL-6 protein




Recommendations
for cytokine storage:





Cytokines
in lyophilized powder form are very stable and can be stored for several years
at -20℃ or -80℃. Freeze-dried powder should be dissolved before use and then
added to the culture medium in liquid form. The dissolved cytokines can only be
stored for a short time (about 1 week) at 4℃. For long-term preservation, first
prepare a diluent (which must contain carrier protein, such as 0.1% BSA, 5%HSA,
or 10% FBS), and then sub-pack and freeze at -20℃ or -80℃. Repeated freezing
and thawing must be avoided, as each freezing and thawing will cause partial
inactivation of proteins.

2019年10月10日星期四

Abbkine Meets You at 17th International Immunology Congress (IUIS 2019)

Abbkine
invites you to visit IUIS 2019, Beijing, China.





Abbkine featured products and services will be displayed at the exhibition. There always be one type can flash into your eyes. Participate in interaction, more surprises are waiting for you!





Date: October
19 – 23, 2019





Booth:#D22,level 4





Address: China
National Convention Center, Beijing, China





About: The 17th International Congress of Immunology (IUIS 2019) will be held from October 19 – 23, 2019 at the China National Convention Center, Beijing, China. IUIS 2019 promises to be an unforgettable event that will bring together delegates from all over the world. We anticipate over 5000 participants, including international leaders at the forefront of the discipline that will present the most recent advances in basic immunology and clinical translation.